Geom Therapeutics, founded as a joint venture with LegoChem Biosciences, focuses on developing novel antibiotics to combat multidrug-resistant Gram-negative infections. Their core mission is to address the growing global health threat posed by antibiotic resistance. The company's flagship product, GT-1, is designed to treat severe infections that are resistant to existing treatments, positioning Geom Therapeutics at the forefront of antibiotic innovation.
Notable affiliations include LegoChem Biosciences, a publicly traded Korean biotechnology company and the original developer of GT-1. Geom Therapeutics has achieved significant milestones in antibiotic research and development, contributing to the critical need for new treatments in the healthcare industry. Their work has the potential to make a substantial impact on public health by providing effective solutions for previously untreatable infections.
